English
Regional settings| Spread | 0.07 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 7.78 |
| Open | 7.87 |
| 1-Year Change | 5.07% |
| Day's Range | 7.16 - 7.87 |
Pulse Biosciences, Inc. is a novel bioelectric medicine company. The Company's Nano-Pulse Stimulation (NPS) technology platform is designed to send energy pulses to cells in order to alter the function of the internal cellular organelles, including the mitochondria and endoplasmic reticulum, without disrupting extracellular tissue. Its commercial product CellFX System is is designed to function on the basis of a non-thermal mechanism of action in a biophysical disruption brought about by the tunable speed and amplitude of NPS pulses interacting with the physical structure of cells. The CellFX System includes a multi-use handpiece and an initial suite of five single use dermatology treatment tips.
BRIEF: For the nine months ended 30 September 2021, Pulse Biosciences Inc revenues increased from $0K to $574K. Net loss increased 34% to $48.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Medical therapy segment loss increase of 11% to $14.3M, United States segment loss increase of 11% to $14.3M.
